PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology

Core Viewpoint - The initiative led by PharosAI aims to create one of the world's largest multimodal cancer datasets using 10x Genomics' Xenium spatial platform, enhancing precision medicine through advanced AI models and analytical tools [1][3]. Group 1: Initiative Overview - PharosAI is a research consortium formed by four leading UK institutions, including King's College London and Queen Mary University of London, to leverage clinical expertise and advanced technologies for cancer research [2][3]. - The project is supported by £18.9 million from the UK Government's Research Ventures Catalyst, along with contributions from charities and industry partners, to develop AI-ready datasets for earlier diagnosis and new treatment discoveries [1][5]. Group 2: Technological Framework - The Xenium spatial platform will transform decades of archived NHS cancer samples into high-resolution, multimodal datasets, facilitating the development of AI models for diagnosis and drug discovery [2][4]. - The initiative will initially focus on breast cancer, with plans to expand to lung and pancreatic cancer, utilizing thousands of clinical tissue samples to uncover previously hidden patterns [3][5]. Group 3: Expected Outcomes - By combining genomic, transcriptomic, imaging, and spatial biology data, PharosAI aims to produce datasets that enable researchers to ask broader questions and accelerate the discovery of new diagnostics and therapies [3][5]. - The program is designed to democratize access to these datasets, ensuring they are available to a wide community of researchers and innovators, positioning the UK as a leader in AI-driven cancer research [5].